Kornimate/medical-research-clean huggingface dataset:
effect of helicobacter pylori eradication on gastroesophageal refiux disease (gerd)

Conditions: GERD

Summary: evaluate the effect of h.pylori eradication on gastroesophageal-reflux disease and symptoms improvement

heiicobacter pyiori (h.pyiori) is a gram-negative spiral shaped bacterium that affects up to 50% of the population worldwide, with a higher prevalences in the developing countries,gastroesophageal reflux disease (gerd) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life.gerd is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophago-gastric junction barrier resulting in exposure of the esophagus to acidic gastric contents, clinically, gerd typically manifests with symptoms of heartburn and regurgitation. it can also present in an atypical fashion with extra-esophageal symptoms such as chest pain, dental erosions, chronic cough, laryngitis, or asthma.the relationship between h. pylori and gastroesophageal reflux disease (gerd) is still unclear, and the effect of h. pylori eradication on gerd treatment is unknown.several studies have shown the inverse relationship between the occurrence of gerd and h.pyiori infection, in particular an increased severity of the disease is documented in patients with pre-existing symptoms .it has been showed that a markedly resolution of dyspepsia in patients at whom the eradication therapy was successful when compared with subjects with a persistent infection

Eligibility criteria:
inclusion criteria: * all patients diagnosed as gerd clinically and endscopically. exclusion criteria: * no exclusion criteria

Keywords: helicobacter pylori
evaluation of treatment satisfaction and preference for sumavel dosepro in the treatment of migraine

Conditions: Migraine

Summary: the purpose of the study is to evaluate the treatment satisfaction of subjects using sumavel dosepro to treat their moderate to severe migraines.

single arm, open-label, multicenter study to evaluate the treatment satisfaction, treatment confidence, and subject preference for sumavel dosepro in adult subjects diagnosed with migraines and currently treated with triptans. subjects will treat up to 4 migraines over a 60 day period and complete migraine diaries and questionnaires.

Eligibility criteria:
inclusion criteria: * history of 2 to 6 migraine headaches per month * migraines should have been present for at least 1 year with age at onset of migraine less than 50 years * history of 24 hours of freedom between migraine attacks * current users of triptan medications * able to distinguish interval or other non-migrainous headaches from typical migraine * general good health exclusion criteria: * history or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes * significant underlying cardiovascular diseases including uncontrolled hypertension * hemiplegic or basilar migraine * history or diagnosis of severe hepatic or renal impairment * history of epilepsy or seizure or other serious neurologic condition * history of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs including sulphonamides * history of scleroderma (systemic sclerosis) * pregnant or breastfeeding * use of contraindicated prescription medications, monoamine oxidase inhibitors (mao-a), selective serotonin reuptake inhibitors, or lithium agents

Keywords: migraine treatment satisfaction
calcium, protein and gut hormones

Conditions: Obesity; Diabetes

Summary: gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (t2d). milk protein and calcium can each potentiate gut hormones following meal ingestion in humans. however, these nutrients may interact synergistically (and with other minerals in milk) such that specific co-ingestion of these nutrients is required to obtain the full therapeutic potential for metabolism and energy balance. this proposal is to perform a pilot study on the effect of co-ingesting capolac® plus protein on circulating gut hormone responses.

participants will be asked to arrive to the laboratory between 08:00 and 10:00 am after not eating for between 8-14 hours i.e. in a fasted state (water intake is permitted and encouraged). participants will then be given one of three test drinks: 1) calcium citrate (1000 mg); 2) milk mineral supplement (equating to 1000 mg calcium); or 3) milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g). each of these drinks will also contain 500 ml of water and artificial sweetener (80 mg sucralose). blood samples will be taken before, and at 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test drink to determine the concentrations of gut hormones (gip, glp-1 and pyy) circulating in the bloodstream. we will also ask participants to complete an appetite questionnaire at baseline and every 30 minutes after ingestion of the test drink to assess their appetite sensations. after the 120-minute time point, we will remove the cannula and the trial day will be complete.

Eligibility criteria:
inclusion criteria: * healthy men and women age between 18-65 yrs. * able to consume provided supplement. * weigh stable for the past 3 month (no change within 3%). exclusion criteria: * any previous or current metabolic, cardio-pulmonary or musculoskeletal disease * not between the ages of 18-65 years * a body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared) * taking medications that may influence your metabolism * plans to change your lifestyle (diet and/or physical activity) during the study period * not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions. * current smoker

Keywords: calcium citrate, dairy product, whey protein, appetite, metabolism
hydrocodone compared to acetaminophen and ibuprofen for post-nail procedure analgesia

Conditions: Nail Diseases; Nail Abnormality

Summary: the purpose of this study is to assess the safety and efficacy of ropivacaine and hydrocodone for nail-procedure associated pain management. the investigators hypothesize that ropivacaine with hydrocodone will be superior to ropivacaine with acetaminophen and ibuprofen for managing pain.


Eligibility criteria:
inclusion criteria: * patients undergoing fingernail or toenail, excision, or shave biopsy * must understand and voluntarily sign an informed consent form * must be male or female and aged 18-95 years at time of consent * must be able to adhere to the study visit schedule and other protocol requirements exclusion criteria: * subject is unable to provide written informed consent for any reason * subject has peripheral vascular disease, arterial insufficiency, peripheral neuropathy * subject is on aspirin, nsaids, or consumes a chronic medication for control of any other chronic pain * subject has a history of opioid or alcohol use disorder * subject has a history of peptic ulcer disease, gastritis, chronic renal insufficiency or a history of kidney disease, or has underlying liver disease * subject has a history of severe constipation * subject is sensitive or allergic to any of the elements included in this study * subject is unable to complete the required pain dairy * subject is pregnant, planning pregnancy, or nursing

Keywords: nail diseases nail biopsy nail procedure pain management
heliox in preterm infants with respiratory distress syndrome

Conditions: Respiratory Distress Syndrome

Summary: heliox can lower respiratory resistance, improve the oxygenation, reduce respiratory distress and lung injury caused by mechanical ventilation.

heliox can improve the oxygenation, reduce respiratory distress and lung injury caused by mechanical ventilation. heliox has not been widely used. more studies on the effects and safety of heliox in addition to nippv and mechanical ventilation should be tried.

Eligibility criteria:
inclusion criteria: * gestational age more than 28 weeks and less than 32 weeks * diagnosed as respiratory distress syndrome * need to use nippv ventilation * no congenital diseases or hereditary diseases * with an informed consent form exclusion criteria: * with congenital diseases or hereditary diseases * intubated in the delivery room * need surgery
bioflow-iii austria satellite registry

Conditions: Coronary Artery Disease; Myocardial Ischemia

Summary: this registry is a clinical post-market evaluation of the orsiro less in subjects requiring coronary revascularization with drug eluting stents (des).

for the majority of coronary artery disease (cad), treatment with percutaneous transluminal coronary angioplasty (ptca) provides high initial procedural success. however, the medium to long-term complications range from rather immediate elastic recoil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. the reported incidence of restenosis after ptca ranges from 30%-50%. such rates of recurrence have serious economic consequences. bare metal stents (bms), designed to address the limitations of ptca, reduced the angiographic and clinical restenosis rates in de novo lesions compared to ptca alone and decreased the need for cabg. bms substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20%-40% of cases, necessitating repeat procedures. the invention of drug eluting stents (des) significantly improved on the principle of bms by adding an antiproliferative drug (directly immobilised on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. the introduction of des greatly reduced the incidence of restenosis and resulted in a better safety profile as compared to bms with systemic drug administration. these advantages and a lower cost compared to surgical interventions has made des an attractive option to treat coronary artery disease. this observational registry is designed to investigate and collect clinical evidence for the clinical performance and safety of the orsiro drug eluting stent system in an all-comers patient population in daily clinical practice.

Eligibility criteria:
inclusion criteria: * symptomatic coronary artery disease * subject has signed informed consent for data release * subject is geographically stable and willing to participate at all follow-up assessments * subject is ≥ 18 years exclusion criteria: * subject did not sign informed consent for data release * pregnancy * known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for pci, stainless steel, sirolimus or contrast media * planned surgery within 6 months of pci unless dual antiplatelet therapy will be maintained * currently participating in another study and primary endpoint is not reached yet.

Keywords: international multicenter observational registry orsiro drug eluting stent (des) stenting treatment of coronary artery disease coronary revascularization percutaneous coronary intervention stemi nstemi ischemia angina subgroups acute myocardial infarction diabetes small vessels chronic total occlusion (cto)
transcranial magnetic stimulation for low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to test whether non-invasive brain stimulation, such as transcranial magnetic stimulation (tms) may alleviate pain associated with various chronic pain conditions. we will test various methods of tms to identify a treatment approach that may reduce the symptoms of chronic pain for the patient.


Eligibility criteria:
inclusion criteria: * age 18 or older * patient with chronic low back pain * meets minimum pain level criteria * ability to perform the experimental task and procedures exclusion criteria: * mri contraindication if an mri exam is required per protocol * tms contraindication * history of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher. * neurologic illness that would interfere with brain integrity * current medical condition or medication use that would interfere with study procedures or data integrity, at the discretion of the researcher. * currently pregnant or planning to become pregnant. * on going legal action or disability claim.
effect of prolonged nightly fasting on immunotherapy outcomes in hnscc - role of gut microbiome

Conditions: Head and Neck Cancer

Summary: this study aims to evaluate if eating within an 8-10-hour window during the day, without any caloric restriction, can lead to better response rates to immunotherapy in head and neck cancer patients.


Eligibility criteria:
inclusion criteria: * newly diagnosed recurrent /metastatic head and neck squamous cell cancer that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy) and initiating standard of care immune checkpoint blocker- (nivolumab, pembrolizumab, atezolizumab, avelumab or durvalumab with or without chemotherapy), for the first time. * patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in recist version 1.1. * eastern cooperative oncology group (ecog) performance status of 0 to 1. exclusion criteria: * bmi\< 18.5. * diabetes mellitus, hyperthyroidism, pregnancy, any eating disorder including anorexia nervosa or bulimia, metabolic disorders that may affect gluconeogenesis or adaptation to short fasting periods * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disease requiring systemic steroids, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * patients who have known leptomeningeal metastases or untreated or symptomatic brain metastases. treated, asymptomatic brain metastasis can be included.

Keywords: intermittent fasting
immunogenicity and safety of hepatitis a among people aged 18-50 years old

Conditions: Hepatitis A

Summary: this study is conducted among people aged 18-50 in dandong city, an area with a high incidence of hepatitis a in recent years. 1000 qualified pariticipants with signed informed consent will be screened for anti-hav antibodies by collecting blood sample of 3ml. one dose of hepatitis a vaccine will be administrated to all the pariticipants. negative anti-hav antibodies-negative subjects will recieve the second dose of hepatitis a vaccination, and 400 of them will be randomly selected and assigned to 4 groups with different interval of vaccination(6 month, 18 months, 36 months and 60 months). blood samples will be collected before vaccination of each dose and on 28 days after each dose of vaccination to anti-hav antibody test. safety data will be collected within 28 days after each vaccination with a smartphone mini-program.


Eligibility criteria:
inclusion criteria: * adults aged 18-50; * adults can understand and sign the informed consent form voluntarily; * adults can provide valid and legal identity certificate. exclusion criteria: * a history of hepatitis a infection; * previously vaccinated with inactivated hepatitis a vaccine, live attenuated hepatitis a vaccine, or hepatitis a and b combined vaccine; * allergic constitution or have severe allergic reaction to vaccines in the past (such as acute allergic reaction, angioedema, dyspnea, etc.); * pregnant women and lactating women; * people suffering from uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barré syndrome, demyelinating diseases, etc.); * patients with fever during vaccination, or acute exacerbation of chronic diseases, or patients with uncontrolled severe chronic diseases, or suffering from acute diseases; * received other research drugs within 30 days before vaccination with the experimental vaccine; * have received a live attenuated vaccine within 14 days before vaccination with the experimental vaccine; * have received subunit or inactivated vaccine within 7 days before vaccination with experimental vaccine; * other conditions that are not suitable for vaccination judged by the researcher.

Keywords: immunogenicity and safety of vaccine hepatitis a vaccine vaccination schedule
effect of methylprednisolone on complement activation in patients undergoing total knee-arthroplasty

Conditions: Osteoarthrosis

Summary: this study evaluates the pathophysiological effects of a single dose of methylprednisolone administered prior to total knee-arthroplasty surgery. the investigators examine the effect on complement activation. half of participants will receive intravenous solu-medrol 125 mg, while the other half will receive placebo. the investigators hypothesize that the group receiving methylprednisolone will experience beneficial inhibition of the undesirable parts of the complement activation.

the anti-inflammatory effects of glucocorticoids are well known. the beneficial effects on postoperative pain, postoperative nausea and vomiting are well-documented. anaesthesia and surgery are associated with a dramatic increase in the inflammatory response. the complement system participates in the disposal of products due to inflammatory damage. the complement activation generates proinflammatory mediators which amplifies the tissue damage and the inflammation. glucocorticoid administration prior to surgery is thought to effectively reduce the inflammatory response and the activation of the complement system. the effect of glucocorticoids on specific complement markers after surgery is unknown and calls for further investigation. this study is embedded in a primary study registrated as: nct02319343 for further details please view the eudract registration: eudract nr.: 2014-003395-23

Eligibility criteria:
inclusion criteria: * osteoarthrosis * undergoing total unilateral knee-arthroplasty surgery * speak and understand danish * have given informed consent exclusion criteria: * revision, bilateral or uni chamber knee-arthroplasty surgery * general anaesthesia * allergy or intolerance towards methylprednisolone * local or systemic infection * permanent systemic treatment with steroids within 30 days preoperatively * insulin-dependent diabetes * active treatment of ulcer within 3 months preoperatively * cancer disease * autoimmune disease incl. rheumatoid arthritis * pregnant or breast feeding women * menopause \<1 year

Keywords: glucocorticoid complement activation knee arthroplasty, total
efficacy and safety of twice daily 60mg azd9668 in copd for 12 weeks in patients on background budesonide/formoterol

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the primary objective is to evaluate the efficacy of azd9668 compared with placebo in symptomatic copd patients by assessing the effects on lung function and symptoms of copd


Eligibility criteria:
inclusion criteria: * diagnosis of copd with symptoms over 1 year * fev1/fvc \ = 30 and \< 80 % of predicted post-bronchodilator * symptomatic copd for a total of 7 days in the two weeks prior to randomisation * at least 1 copd exacerbation from 4 weeks to 12 months before the screening visit exclusion criteria: * past history or current evidence of clinically significant heart disease * current diagnosis of asthma * patients who require long term oxygen therapy * worsening of copd requiring treatment with antibiotics, an increase in inhaled steroid dose and/or oral steroids within 4 weeks of study visit 1b

Keywords: chronic obstructive pulmonary lung respiratory disease efficacy placebo-controlled copd fev1 st georges respiratory questionnaire
fibrin glue versus tacked fixation in groin hernia repair (tapp)

Conditions: Inguinal Hernia; Femoral Hernia

Summary: in this study the researchers want to compare fibrin glue versus tacked fixation in fixation of the mesh in laparoscopic groin hernia repair. the primary endpoints are early pain in the first 3 days postoperative days. moreover, the researchers investigate general well-being, fatigue, seroma, haematoma, postoperative nausea and vomiting. thirdly, they are investigating chronic pain and clinical recurrence.


Eligibility criteria:
inclusion criteria: * unilateral groin hernia * planned laparoscopic inguinal or femoral herniorrhaphy * asa i-iii * fluent danish exclusion criteria: * converting to open operation * low compliance * daily use of morphine or similar drugs daily in the last month * complications to the operation

Keywords: tapp early pain well-being seroma haematoma fibrin glue tacks
phase iv clinical trial to evaluate the efficacy and safety of plbcr and aceclofenac in the treatment of patients with osteoarthritis of the knee

Conditions: Osteoarthritis of Knee

Summary: a multicenter, randomized, double-blinded, parallel, active-controlled, phase iv clinical trial to evaluate the efficacy and safety of plbcr and aceclofenac in the treatment of patients with osteoarthritis of the knee


Eligibility criteria:
inclusion criteria: * both male and female who is over 35year-old and below 80year-old * patient who diagnosed as kellgren \& lawrence stage i\~iii by x-ray * osteoarthritis patient who is stable within 3months form starting this clinical trial * patient who is over 40mm in 100mm pain vas at visit 2 * patient who agreed to participate this clinical trial spontaneously exclusion criteria: * second osteoarthritis * patient who has inflammatory disease which can effect efficacy outcomes such as bursitis, tenosynovitis, rheumatoid arthritis, etc. * patient who diagnosed as gastric ulcer or gi disease by esophagogastroduodenoscopy * patient who had joint surgery within 12months form screening visit of this clinical trial or planned to operate in this clinical trial period * patient who has had artificial joint surgery of knee * malignant tumor patient * patient who has taken psychopharmaceutical or narcotic analgesics over 3months continuously * patient who took steroid by oral, inhalation or intraarticular injection within 3months form screening visit of this clinical trial * patient who took intraarticular hyaluronic acid injection of knee within 2months form screening visit of this clinical trial * patient who cannot take nsaids because of disease or medicine * allergy of aspirin of other nsaids * patient who has to handle his/her pain by or for cabg * galactose intolerance, lactose intolerance or glucose-galactose malabsorption * inflammatory bowel disease such as ulcerative colitis or crohn's disease * moderate renal disease * moderate hepatic disease * moderate hypertension(sbp=\>160mmhg, dbp=\>100mmhg) * female who consents to contracept * patient who is not appropriate for this clinical trial